BMS (BMY) - יחס חוב להיוון בספרים

AI-driven bioscreening robotization optimizes costs for Bristol-Myers Squibb (BMY), enhancing profitability. On GURU.Markets, the current debt-to-equity structure reflects borrowing dynamics, where 2.14 forms the current metric value. Dominance in oncohematology ensures a steady cash flow for investments, while the aggressive acquisition of small biotechs strengthens the new molecule portfolio, mitigating internal development risks.

This indicator measures the ratio of total liabilities to total equity, determining the degree of financial stability and the risk of default amid changing interest rates. By analyzing the share of debt financing in the balance sheet capitalization at 2.14, an investor assesses the ability of Bristol-Myers Squibb (BMY) to sustain new drug development and mitigate the risks of patent expiration without a critical debt burden.